Eyewire News

Featured Story

06.04.2026

Tavo Biotherapeutics Announces $17 Million Series A Financing to Advance Novel Therapies in Glaucoma and Retinal Disease

Key Takeaways Tavo Biotherapeutics closed a $17 million Series A financing to advance its pipeline of innovative therapies targeting glaucoma and retinal disease Tavo Biotherapeutics announced the successful closing of a $17 million Series A financing led by Pureos Bioventures with participation by Polaris Partners and continued support from existing investor Tau Capital. The proceeds will be used to advance Tavo's pipeline of innovative therapies targeting glaucoma and retinal disease.

Read Story

Latest News Stories

06.04.2026

NEI-Supported Researchers Launch Open-Access Tool to Expand Access to Amblyopia Care for Children

Phase 3 Trial Evaluating Viridian's Veligrotug for Thyroid Eye Disease Publsihed image

06.04.2026

Phase 3 Trial Evaluating Viridian's Veligrotug for Thyroid Eye Disease Published

06.03.2026

Study Examines Postoperative Complications Risk of LASIK and PRK

06.02.2026

New Four-Year Study Examines Faricimab's Durability in Diabetic Macular Edema

University of Miami Names Pradeep Y. Ramulu, MD, as Chair of Bascom Palmer Eye Institute image

06.02.2026

University of Miami Names Pradeep Y. Ramulu, MD, as Chair of Bascom Palmer Eye Institute

06.02.2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep in Neurotrophic Keratitis

06.01.2026

State Investment to Fund first College of Optometry in Georgia

Bausch + Lomb Launches Preservative-Free Blink Triple Care Eye Drops in the US image

06.01.2026

Bausch + Lomb Launches Preservative-Free Blink Triple Care Eye Drops in the US

Rayner Launches Optiesis Cohesive OVD Family image

06.01.2026

Rayner Launches Optiesis Cohesive OVD in Europe

05.29.2026

Oculis Does Not Meet Primary Endpoint in Phase 3 DIAMOND Program of OCS-01 in DME

05.29.2026

Study Finds Atopic Dermatitis May Raise Risk of Retinal Detachment

05.29.2026

Samsung Bioepis Launches Opuviz Aflibercept Biosimilar Across Europe

Therini Bio Doses First Patients in Phase 1b Trial of THN391 for DME image

05.28.2026

Therini Bio Doses First Patients in Phase 1b Trial of THN391 for DME

Maculaser Secures New Investment to Advance Temperature-Controlled Retinal Laser Therapy in Europe image

05.28.2026

Maculaser Secures New Investment to Advance Temperature-Controlled Retinal Laser Therapy in Europe

05.27.2026

Nanoscope Therapeutics Selects InspiroGene by McKesson to Support Distribution of Retinal Therapy

Cure Blindness Project Releases 2025 Impact Report Highlighting Global Reach and Restored Vision image

05.27.2026

Cure Blindness Project Releases 2025 Impact Report Highlighting Global Reach

Outlook Therapeutics Wins FDA Appeal for Lytenava, Plans BLA Resubmission in June image

05.26.2026

Outlook Therapeutics Wins FDA Appeal for Lytenava, Plans BLA Resubmission in June

Oculus Launches AI-Assisted Tool to Improve Meibomian Gland Dysfunction Diagnostics image

05.26.2026

Oculus Launches AI-Assisted Tool to Improve Meibomian Gland Dysfunction Diagnostics

05.26.2026

Researchers in Japan Link Drinking Habits to Faster Progression of Presbyopia

View More